Compare AbbVie Inc (ABBV) vs iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs iShares S&P GSCI Commodity-Indexed Trust ETF — how do they compare? AbbVie Inc trades at $253.24 (market cap $449.91B), while iShares S&P GSCI Commodity-Indexed Trust ETF trades at $29.96. The key difference: AbbVie Inc pays a 2.72% dividend while iShares S&P GSCI Commodity-Indexed Trust ETF pays none, and AbbVie Inc is trading nearer its 52-week high, iShares S&P GSCI Commodity-Indexed Trust ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | GSG | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $261.07 | $34.77 |
52-Week Low | $184.85 | $22.06 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
GSG trades at $28.89, up 1.83% today, with a bullish technical signal but mixed moving averages and neutral oscillators. Recent news highlights institutional interest, with JPMorgan Chase increasing its stake by 224.3% in Q3 2025 (SEC filing, 2026-04-07). Commodity ETFs like GSG are gaining attention amid inflation fears and supply constraints, as noted by Zacks Investment Research (2026-04-07).
The outlook for GSG is supported by strong commodity market trends and institutional accumulation, but risks include volatility from geopolitical events and inflation shifts. Key support sits at $28, with resistance near $29. Wall Street sentiment is cautiously optimistic due to macroeconomic tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →
